Welcome to Bristol Myers Squibb Washington

Bristol Myers Squibb’s robust and growing presence in Washington state is transforming the way difficult-to-treat cancers are approached.

Our teams in Seattle and Bothell discover, develop, manufacture and commercialize therapies in Immuno-Oncology (I-O) and cell therapy. Through continued leadership in the rapidly developing fields of engineered cell-based therapies and biotherapeutics aimed at harnessing the power of immune cells to enhance or restore the body’s ability to fight cancer, we seek to advance novel treatments for cancer patients with precision and purpose. 

Meet our team

Learn about our leaders who are making a difference in Washington state.

Teri Foy, Seattle site head, and her work at Bristol Myers Squibb  >

Teresa (Teri) Foy, Ph.D., is an immunologist with more than 25 years of biotechnology and pharmaceutical industry experience developing novel therapeutics in the areas of oncology and inflammation.

Chris Holt, Bothell site head, and his work at Bristol Myers Squibb >

Chris Holt leads the day-to-day operations of Bristol Myers Squibb’s Bothell site and oversees cell therapy manufacturing operations to deliver personalized (autologous) therapies to patients globally.

Doug Bassett and his work at Bristol Myers Squibb >

Doug Bassett leads a team of data scientists and analysts who harness the power of big data, artificial intelligence (AI) and machine learning in search of deeper insights into disease biology.

Justine Dell’Aringa and her work at Bristol Myers Squibb >

Justine Dell’Aringa is an associate director of Translational Medicine, working in Bristol Myers Squibb’s Immuno-Oncology and Cell Therapy Thematic Research Center. 

Alison Fitch and her work at Bristol Myers Squibb >

Alison Fitch is director of scientific operations and strategy for the Immuno-Oncology and Cell Therapy (IO-CT) Thematic Research Center at Bristol Myers Squibb’s Seattle site.

Leanne Peiser and her work at Bristol Myers Squibb >

Leanne Peiser, PhD, leads a team working on translational research evaluating cellular therapies and select immuno-oncology assets in clinical development in lymphoma, acute myeloid leukemia and solid tumors.

PV Sivakumar and his work at Bristol Myers Squibb >

Pallavur (PV) Sivakumar, PhD, leads discovery efforts for the early immuno-oncology and cell therapy pipeline across all modalities to find the next innovative therapy for treating patients with various cancers.

Join us as we transform patient lives through science 

Everyday, each of us work to improve outcomes of patients fighting serious diseases. Together we’re building a better future for each other and the patients who need us the most. 

Driving innovation forward in Washington state

Learn about our broad scope of scientific innovation in Washington state.

Confronting the complexities of cancer >

Bristol Myers Squibb is driven to understand human biology and the complexities of cancer in order to advance the next generation of cancer therapies.

Looking to the future of cell therapy >

Bristol Myers Squibb is pursuing a multitude of diverse approaches in cell therapy to attack disease from new perspectives. 

Blueprint for a breakthrough: Applying research learnings beyond the lab >

With multiple cell-based therapeutic approaches under investigation in blood cancers and beyond, Bristol Myers Squibb researchers like Justine Dell’Aringa are harnessing the immune system to reimagine the future of cancer treatment.

Cell therapy’s got talent – and is looking for more >

Major recruitment efforts are underway at Bristol Myers Squibb.

‘Serial killer’ CAR T cells target and destroy tumor cells in Bristol Myers Squibb lab >

BMS is a leader in autologous chimeric antigen receptor (CAR) T cell therapy, a type of cancer immunotherapy where a patient’s own T cells are genetically engineered to recognize and bind to proteins found on the surface of certain cancer cells. This video, shared by the Discovery Research team of the Immuno-Oncology and Cell Therapy (IO-CT) thematic research center (TRC) in Seattle, Washington, shows a tumor cell being destroyed by CAR T cells. 

Community impact

Learn how we are making a difference in communities across Washington state.

Smile, you’re on camera, talking STEM >

Through a partnership with Seattle’s Pacific Science Center, nearly 30 Bristol Myers Squibb scientists shared their STEM expertise with the next generation.

People and business resource groups >

People and Business Resource Groups (PBRGs) represent one key strategy we use to support the business objectives, career advancement and development needs of our employees.

In pursuit of more female scientists: Breaking barriers for women in STEM >

Teri Foy, Ph.D., discusses her advocacy for women in STEM and frequently meets and presents to girls and women at schools in the Seattle area. 

Improving science education >

We support programs and organizations that address unmet medical needs, help students grow through STEM education, and deliver basic human services to our neighbors.

Washington state regional fact sheet >

Learn more about our impact in Washington

Additional resources

Learn more about our scientific approaches and innovation.

Cell therapy resources >

Discover how cell therapies are unlocking new potential in cancer research.

Understanding cell therapy >

Learn more about cell therapy and our approach to cell therapy research.

Cell therapy manufacturing infographic >

Bristol Myers Squibb is advancing cell therapy research through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highlight trained manufacturing teams.

Understanding the CAR T cell therapy treatment experience >

Learn more about the patient journey on CAR T.

Targeting cancer with CAR T cell therapy >

Read about the science of CAR T cell therapy and cutting-edge research.

Explore our comprehensive approach to cancer research >

Learn how our comprehensive pipeline, spanning multiple approaches across platforms and modalities, sets us apart and enables us to fulfill our vision of transforming patients’ lives through science.